Actively Recruiting
A Prospective Observational Study to Assess the Reliability and Validity of the Multi-Luminance Shape Discrimination Test (MLSDT) With 9 Objects
Led by Nanoscope Therapeutics Inc. · Updated on 2025-03-24
30
Participants Needed
1
Research Sites
1 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the accuracy and reliability of the Multi-Luminance Shape Discrimination Test (MLSDT) with 9 objects in people with moderate to severe vision impairment. The study focuses on participants diagnosed with Stargardt Disease (STGD) or Geographic Atrophy (GA) caused by age-related macular degeneration (AMD). The goal is to compare MLSDT results with standard visual acuity measurements using the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart and to assess how well the test measures functional vision across different levels of vision loss. Participants are divided into three groups: those with normal vision, moderately impaired vision, and severely impaired vision, based on their best-corrected visual acuity (BCVA) scores and clinical diagnosis. The study involves testing each participant's vision using the MLSDT without and then with the use of a wearable low-vision magnifying device called eGlasses. Their performance on the MLSDT will be compared to ETDRS test results under the same conditions. During the study, participants will undergo vision tests with and without eGlasses, and their visual acuity will be measured using the ETDRS chart. Researchers will evaluate the test's repeatability and variability, along with relationships between MLSDT scores and BCVA. The primary outcome is the MLSDT score in normal and severely visually impaired participants with STGD or GA, assessed within 15 days. Participants' ability to complete the tests and maintain vision stability will be monitored throughout the study period.
CONDITIONS
Brief Title
A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Males and females aged 18 years or older
- Able to understand and provide informed consent
- Able to comply with all testing procedures
- Eligible for one of three vision groups: Cohort 1: Normal vision with BCVA 20/16 to less than 20/40 in each eye Cohort 2: Moderate vision impairment with BCVA 20/40 to less than 20/200 and diagnosis of Stargardt Disease or Geographic Atrophy Cohort 3: Severe vision impairment with BCVA 20/200 to 20/800 and diagnosis of advanced Stargardt Disease or Geographic Atrophy
- Clinical diagnosis of Stargardt Disease or Geographic Atrophy for cohorts 2 and 3
- If anti-VEGF therapy was received within 2 weeks before enrollment, participants must show 3 months of stable vision and be free of fluid on OCT imaging
You will not qualify if you...
- Participation in any interventional clinical trial or receipt of investigational drug within the past 6 months
- Presence of eye conditions other than Stargardt Disease or Geographic Atrophy that impair vision, such as corneal opacity, significant cataract, or glaucoma-related visual field loss
- Anti-VEGF injection within 2 weeks prior to study
- Neurological conditions that impair vision
- Inability or refusal to perform MLSDT or BCVA tests
- Presence of retinal prosthesis such as ARGUS-II
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 15 days
Participants undergo vision assessments including the Multi-Luminance Shape Discrimination Test (MLSDT) and best-corrected visual acuity (BCVA) testing to evaluate functional vision.
1 to 3 visits depending on cohort assignment
Duration - Up to 15 days post initial testing
Participants are observed to assess the reliability and validity of the MLSDT over time.
Follow-up visits as scheduled depending on cohort
Trial Site Locations
Total: 1 location
1
Retina of North Texas,
Dallas, Texas, United States, 75243
Actively Recruiting
Research Team
N
Nozhat Choudry, Ph.D
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here